IP Verse

Breast Cancer Therapeutics - EP2618833

The patent EP2618833 was granted to Imba Institut FR Molekulare Biotechnologie on May 2, 2018. The application was originally filed on Sep 22, 2011 under application number EP11758242A. The patent is currently recorded with a legal status of "Revoked".

EP2618833

IMBA INSTITUT FR MOLEKULARE BIOTECHNOLOGIE
Application Number
EP11758242A
Filing Date
Sep 22, 2011
Status
Revoked
Oct 18, 2019
Grant Date
May 2, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

DEHMEL & BETTENHAUSEN PATENTANWALTE PARTMBBFeb 1, 2019RUCKERLADMISSIBLE
PATENTANWALTE ISENBRUCK BOSL HORSCHLER PARTG MBBJan 28, 2019LAHRTZADMISSIBLE

Patent Citations (27) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0873998
DESCRIPTIONEP0911342
DESCRIPTIONEP1144623
DESCRIPTIONEP2003203
DESCRIPTIONUS2002162126
DESCRIPTIONUS2002173478
DESCRIPTIONUS2004167072
DESCRIPTIONUS2008107597
DESCRIPTIONUS5843678
DESCRIPTIONUS6017729
DESCRIPTIONUS6740522
DESCRIPTIONUS7411050
DESCRIPTIONWO02055692
DESCRIPTIONWO02055693
DESCRIPTIONWO02098362
DESCRIPTIONWO03074654
DESCRIPTIONWO2005028633
DESCRIPTIONWO2007128564
DESCRIPTIONWO2010022120
DESCRIPTIONWO9312227
DESCRIPTIONWO9846751
DESCRIPTIONWO9854201
DESCRIPTIONWO9953942
INTERNATIONAL-SEARCH-REPORTWO02098362
INTERNATIONAL-SEARCH-REPORTWO9953942
OPPOSITIONWO02098362
OPPOSITIONWO2012038504

Non-Patent Literature (NPL) Citations (20) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "Amgen preclinical Study Demonstrated Anti-Tumor Activity in Mammary Tumor Model.", Amgen press release, (20100419), pages 1 - 7, XP055572707-
OPPOSITION- BRANSTETTER D et al., "SAN ANTONIO BREAST CANCER SYMPOSIUM", Cancer Research, (20090100), vol. 69, no. 2, pages 1 - 7, XP055572669-
OPPOSITION- HAAS, M.J., "RAN Kling non-skeletal tumors", SciBX, (20100506), vol. 3, no. 18, XP055572650-
OPPOSITION- NAKSHATRI H et al., Mol Cell Biol., (19970700), vol. 17, no. 7, pages 3629 - 3639, XP055572630-
OPPOSITION- T. D. RACHNER, "Modulation und funktionelle Relevanz des RANKL/ TRAIL/Osteoprotegerin-Systems bei Mammakarzinomzellen", Thesis at the Philipps-University Marburg, (20090000), pages 1 - 140, XP055572592-
OPPOSITION- Underwood et al., General and Systematic Pathology, (20090000), page 229, XP055572687-
OPPOSITION- V. SIGL, "The Role of RANK and RANKL in hormone-driven breast cancer", Diploma Thesis at the University of Vienna, (20090000), pages 1 - 83, XP055572579-
OPPOSITION- KOSTENUIK PJ, "Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength", Curr Opin Pharmacol., (20051200), vol. 5, no. 6, pages 618 - 25, XP005134774
OPPOSITION- SCHRAMEK, D. et al., "Osteoclast differentiation factor RANKL controls develop- ment of progestin-driven mammary cancer", Nature, (20101104), vol. 468, no. 7320, pages 98 - 102, XP055572606
OPPOSITION- SCHRAMEK et al., "Osteoclast differentiation factor RANKL controls develop- ment of progestin-driven mammary cancer", Nature, (20101104), vol. 468, no. 7320, pages 98 - 102, XP055572606
OPPOSITION- GONZALEZ-SUAREZ, E. et al., "RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis", Nature, (20101104), vol. 468, no. 7320, pages 103 - 167, XP055009730
OPPOSITION- GONZALEZ-SUAREZ E, "RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis", Nature, (20101104), vol. 468, no. 7320, pages 103 - 107, XP055009730
OPPOSITION- CALLAWAY, E., "Bone-disease drug could treat breast cancer", Nature, (20100929), XP055572620
OPPOSITION- KOCH L, "RANKL inhibition-a new weapon against breast cancer?", Nat Rev Endocrinol., (20110100), vol. 7, no. 1, page 2, XP055572726
OPPOSITION- BELEUT, M. et al., "Two distinct mechanisms underlie progesterone-induced pro- liferation in the mammary gland", PNAS, Illkirch-Cedex, France, (20100103), vol. 107, no. 7, pages 2989 - 2994, XP002621520
OPPOSITION- A. LEIBRANDT et al., "ESCI award lecture: from little mouse to ra- tionale medicine for bone loss", Eur. J. Clin Invest, (20091020), vol. 39, no. 10, pages 842 - 850, XP009144002
OPPOSITION- JACOB AP et al., "Abstract LB-156: A RANKL inhibitor but not a bisphosphonate, zoledronic acid, reduces mammary tumor formation in a carcinogen- and hormone-dependent mouse model", Cancer Research, (20100400), vol. 70, no. 8, pages 1 - 4, XP055572698
OPPOSITION- JACOB, A.P. et al., "Abstract LB-156: A RANKL inhibitor but not a bisphosphonate, zoledronic acid, reduces mammary tumor formation in a carcinogen- and hor- mone-dependent mouse model", Cancer reserach, (20100000), vol. 70, no. 8, XP055572600
OPPOSITION- KEARNS et al., "Receptor Activator of Nuclear Factor KB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease", Endocr Rev., (20080400), vol. 29, no. 2, pages 155 - 192, XP055572655
OPPOSITION- CAMPBELL MC et al., "CAPER as a therapeutic target for triple negative breast cancer", Oncotarget, (20180713), vol. 9, no. 54, pages 30340 - 30354, XP055572643

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents